Chairman John Moolenaar of the House Select Committee on China released a statement following the inclusion of two major pieces of committee-backed legislation—the outbound investment restrictions and the BIOSECURE Act—in the 2026 National Defense Authorization Act (NDAA) conference report.
“This legislation empowers President Trump to better protect our nation by restricting the flow of American capital to Chinese military companies and critical technology sectors. It closely mirrors the bipartisan COINS Act framework championed by the Select Committee in 2024 and the President’s America First Investment Policy from earlier this year. For too long, the hard-earned money of American retirees and investors has been used to build up China’s military and economy. This legislation will help bring that to an end,” Moolenaar said.
He also addressed provisions aimed at protecting genetic data: “The NDAA also protects Americans and their genetic data from growing biotechnology threats from China. The BIOSECURE Act takes defensive action to secure American pharmaceutical supply chains and genetic information from malign Chinese companies—disarming a loaded gun aimed at the well-being of all Americans.”
Moolenaar expressed appreciation for congressional leaders who supported these measures. “I am deeply grateful to Speaker Johnson and Majority Leader Scalise for their support in including this critical legislation in the NDAA, as well as for the tireless efforts of Congressman Andy Barr, Senator John Cornyn, and leaders across Congress who have made this legislation a reality. Our nation is more secure as a result,” he stated.
The new provisions reflect efforts by lawmakers to address national security concerns linked to U.S. investments in China’s defense sector, as well as risks associated with biotechnology firms based in China.
